Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment
Phase 2
Completed
- Conditions
- Heart Failure, CongestiveRenal Insufficiency
- Registration Number
- NCT00159614
- Lead Sponsor
- NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Brief Summary
The purpose of this study is to characterize the safety and tolerability of KW-3902IV and measure its effect on renal function.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- Stable congestive heart failure
- Impaired renal function
- Taking oral loop diuretic
Exclusion Criteria
- Acutely decompensated (unstable) and end stage heart failure
- Diuretics other than loop diuretics
- Pregnant or nursing
- Inability to follow instructions
- Participation in another clinical trial within past 30 days
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method Comparison of KW-3902IV alone or with loop diuretic on renal function.
- Secondary Outcome Measures
Name Time Method